ClinicalTrials.gg
CompletedNCT07076030Updated Jan 28, 2026

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

A Phase 1 interventional study of Petrelintide in Renal Impairment, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
63rd of 113
39 · median 42
Started
2025
with 5 others
Phase 1
54 of 139
1 open now
Registered
135th of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 63rd largest by enrollment of the 113 interventional ones that give a count, is one of 6 that started in 2025, is one of 54 in phase 1, and was the 135th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with comorbidities or related diseases.

The aim of this clinical research study is to investigate whether the effects of petrelintide will be different in people with normal kidney function compared to people with impaired kidney function.

Read the detailed description

This is a Phase 1, open-label, single-center, single dose, parallel-group, non-randomized study to evaluate the pharmacokinetics (PK), safety, and tolerability of petrelintide after a single dose in participants with mild, moderate, or severe renal impairment, and participants with normal renal function. Allocation of participants to the renal function groups will be based on the estimated glomerular filtration rate (eGFR).

Each participant will receive a single subcutaneous dose of petrelintide on Day 1.

Up to 24 participants with normal renal function and 24 participants with renal impairment (8 participants each in the following groups: mild, moderate, or severe renal impairment) will participate in this study.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 65 years (both inclusive) at screening.
  2. (Body Mass Index): 21.0 to 40.0 kg/m2, inclusive, at screening.
  3. Sex: Male and female participants.
  4. Participants with mild, moderate, or severe renal impairment and participants with normal renal function.
  5. For participants with renal impairment: stable renal impairment for 3 months prior to screening.
  6. For participants with Type 2 diabetes mellitus and renal impairment:

    1. (hemoglobin A1c) ≤11% at screening.
    2. On a stable diet and exercise regimen or stable metformin and/or SGLT2i (Sodium-Glucose Cotransporter 2 inhibitors) treatment for at least 3 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Exposure to amylin analogs, including petrelintide (ZP8396) within the last 3 months.
  2. acute illness within 4 weeks prior to Day 1, as judged by the Investigator to potentially interfere with the study conduct and/or results.
  3. Impaired liver function, defined as (ALT) >1.2 times upper normal limit, or >1.2 times upper normal limit, measured at screening.
  4. Presence or history of acute or chronic pancreatitis.
  5. Known clinically significant gastric emptying abnormality (for example, severe gastroparesis, gastric outlet obstruction, gastric bypass operations, or sleeve gastrectomies) or chronic treatment that affects gastrointestinal motility.
  6. Any disorder, unwillingness, or inability, not covered by any of the other exclusions criteria, which in the Investigator´s opinion, might jeopardize the participant´s safety or compliance with the protocol.
  7. Participants with Type 1 diabetes mellitus as declared by the participant.
  8. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long Syndrome).
  9. Presence or history of clinically significant arrhythmias or clinically significant conduction disorders.
  10. A marked baseline prolongation of QT/QTc (e.g. repeated demonstration of a QTc interval >450 ms.
  11. Smoking of more than 10 cigarettes (or equivalent nicotine consumption) per day.

    Tobacco that contains menthol must not be consumed within 7 days prior to study drug administration.

  12. Presence or history of following cardiovascular diseases:

    1. Decompensated heart failure ( (NYHA) class III and IV).
    2. Unstable angina pectoris.
    3. Myocardial infarction within the last 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Group 1 Normal Renal Function

    Each participant will receive a single subcutaneous dose of petrelintide on Day 1.

    Drug: Petrelintide

  • Experimental
    Group 2 Mild Renal Impairment

    Each participant will receive a single subcutaneous dose of petrelintide on Day 1.

    Drug: Petrelintide

  • Experimental
    Group 3 Moderate Renal Impairment

    Each participant will receive a single subcutaneous dose of petrelintide on Day 1.

    Drug: Petrelintide

  • Experimental
    Group 4 Severe Renal Impairment

    Each participant will receive a single subcutaneous dose of petrelintide on Day 1.

    Drug: Petrelintide

Interventions

  • Solution administered with a syringe

    Also known as: ZP8396

06

What researchers measure

Primary outcomes

  1. AUCo-inf of petrelintide

    AUCo-inf: Area Under the Curve from time 0 to infinity

    Time frame: From administration (Day 1) to Last visit (Day 43)

Secondary outcomes

  1. Maximum observed plasma concentration

    Time frame: From administration (Day 1) to Last visit (Day 43)

  2. Time to attain maximum observed plasma concentration

    Time frame: From administration (Day 1) to Last visit (Day 43)

  3. Area under the plasma concentration-time curve from time 0 to infinity

    Time frame: From administration (Day 1) to Last visit (Day 43)

  4. Area under the concentration versus time curve from time zero to last measurable concentration

    Time frame: From administration (Day 1) to Last visit (Day 43)

  5. Terminal elimination half-life

    Time frame: From administration (Day 1) to Last visit (Day 43)

  6. Apparent clearance

    Time frame: From administration (Day 1) to Last visit (Day 43)

  7. Apparent volume of distribution at terminal phase

    Time frame: From administration (Day 1) to Last visit (Day 43)

07

Study locations

1 site
  • Charité Research Organisation GmbH
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Nov 2025, 7 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 20, 2025
StartActual
Apr 15, 2025
Primary completionActual
Nov 25, 2025
CompletionActual
Nov 25, 2025
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076030
Lead sponsor
Zealand Pharma
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Apr 15, 2025
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Jan 28, 2026

Study contacts

Victoria Kegel-Hübner, Dr.med.
principal investigator · Charité Research Organisation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petrelintide

Start the discussion